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Lymphoscintigraphy is an important part of the mapping and
identification of sentinel lymph nodes (SLNs). However, few
studies report its reproducibility, and some concerns prevail.
The aim of the study was to determine the reproducibility of
lymphoscintigraphy performed by different team members fol-
lowing a strict protocol to assess lymphatic drainage and the
location and number of SLNs. Methods: Sixty-eight melanoma
patients were included. All underwent 2 separate lymphoscintig-
raphy studies, which followed the same acquisition protocol. Dis-
cordance was defined as a change in localization or a failure to
identify the SLN in one of the studies. Results: All patients
showed lymphatic drainage, and in all cases at least 1 sentinel
node was identified. In 65 of 68 patients (96%), the findings of the
first lymphoscintigraphy study were similar to those of the sec-
ond. This similarity was also found in the number of sentinel
nodes (171 in the first study and 173 in the second). Eighty per-
cent of patients showed 1–3 SLNs in both lymphoscintigraphy
studies. The 2 studies differed in 3 patients (4%): 2 melanomas
were located on the trunk and 1 on the head and neck. Drainage
was visualized to more than 1 lymphatic basin in 19 patients
(28%) in the first study versus 18 patients in the second study.
Conclusion: Lymphoscintigraphy is highly reproducible in the de-
tection of sentinel nodes in melanoma patients. The classic pro-
tocol of radiotracer injection is reproducible and reliable enough
to guarantee SLN identification, although a slight variation in iso-
lated cases (especially when primary lesions are located on the
trunk or the head and neck regions) is inevitable.
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The technique of sentinel lymph node (SLN) biopsy with
selective lymph node dissection in melanoma patients has been
widely adopted by surgical oncologists as an alternative to
elective lymphadenectomy for patients with clinically negative
regional lymph nodes who are at high risk for nodal metastases
(1,2). The success of this technique has resulted in its use in
the treatment of other cutaneous and noncutaneous malignan-
cies with regional lymphatic metastatic potential (3).
Since its introduction in 1992, lymphoscintigraphy has
been an essential component for preoperative SLN identi-
fication in melanoma and breast cancer. Any lymph node
with direct drainage from the primary tumor (i.e., the SLN)
can be considered as a possible site of metastasis. The SLN
is not necessarily the hottest or closest node, although that is
often the case (4). For preoperative imaging, colloid particles
labeled with 99mTc are currently used. Since SLN biopsy
using presurgical lymphoscintigraphy has been shown to ac-
curately stage the regional lymph nodes, it has been accepted
that this imaging method is a reliable and reproducible ap-
proach for lymphatic mapping assessment from a melanoma
to the draining SLN. The advantages of performing lympho-
scintigraphy are several: identification of all draining hot
nodes and all draining basins, identification of sentinel and
second-tier lymph nodes, and identification of unpredictable
SLNs, including in-transit lymph nodes (i.e., lymph nodes
located between the primary tumor site and a drainage basin)
and aberrant lymph nodes (i.e., lymph nodes located outside
a standard drainage basin). Multiple hot nodes that belong to
a single basin must be differentiated from multiple hot nodes
that drain to separate basins and need to be identified at sur-
gery and examined.
Previous studies have shown a reproducibility rate in the
range of 80%–85% (5–8), with the conclusion that lymphoscin-
tigraphy is not always reproducible and thus may sometimes
produce false-negative SLN results. What is more, a greater
variability in lymphatic drainage pathways has been reported
in patients with cutaneous melanoma in the head and neck or
trunk (9). In these previously mentioned works, the lympho-
scintigraphic procedures were performed by the same inves-
tigator so as to avoid the potential variability of several
different physicians performing the 2 studies.
However, in routine clinical practice lymphoscintigraphy
sometimes needs to be repeated, and different nuclear
medicine physicians and technologists are often involved.
This situation can introduce variables that may have an
adverse effect on the reproducibility of the procedure.
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We devised a study to assess the reproducibility of
lymphoscintigraphy performed by different nuclear medi-
cine team members following a strict protocol to assess




The study ran from December 2009 to July 2011 and involved,
prospectively, 71 patients (33 women, 38 men; aged 22–82 y; mean
age, 50 y) with melanoma. All patients were scheduled for lymphatic
mapping and ultrasonographic study of the lymphatic draining basins
on the same day.
The inclusion criteria for performing lymphatic mapping were
a Breslow thickness either greater than 1 mm or—with some risk
factors (ulceration, high mitotic rate, Clark level IV or V)—less
than 1 mm. The primary lesion was on the lower extremity in 26
patients, on the upper extremity in 9, on the trunk in 24, and on the
head and neck in 12. The mean Breslow thickness was 1.9 mm
(range, 0.7–8.0 mm). The general exclusion criteria were wide
local excision of a previous tumor and patients who did not accept
the study. Another specific exclusion criterion was a lymph node
positively ascertained by ultrasound and subsequent histology.
A first lymphoscintigraphy study was performed for lymphatic
mapping (to select the lymphatic basins to be explored by ultraso-
nography), part of a running protocol in our department that includes
ultrasound and scintigraphy. This first study was done by one of the
nuclear medicine physicians involved in the study. If ultrasound
assessment of those lymph nodes did not reveal any suspicion of node
involvement (in which case it would be ascertained by fine-needle
aspiration cytology), a subsequent SLN biopsy procedure (with a
second lymphoscintigraphy study) was performed some weeks later,
the day before scheduled surgery. This second study was performed by
a different physician from the nuclear medicine team involved in the
study but followed the same strict injection and imaging protocol.
Informed consent was obtained from all patients, and the study
protocol was approved by the Ethics Committee of Hospital Clı´nic,
Barcelona.
Lymphoscintigraphy
Injection Procedure. There is a general consensus that intra-
dermal injection (raising a wheal at each injection site) is the
optimal technique for injecting radiocolloid for lymphatic mapping.
The number and specific site of radiocolloid aliquots to inject varies
according to anatomic region, but the tracer is always injected about
0.5–1.0 cm away from the scar or the tumor margin.
During the first lymphatic mapping procedure, a photograph of
the injection site with skin marks at the points of injection was
taken to reduce the degree of variability when repeating the procedure.
A maximum of 4 tuberculin syringes, each containing 37 MBq of
99mTc-nanocolloid (Nanocoll; GE Healthcare) in 0.1 mL were used.
The total activity administered was therefore between 74 and 148
MBq in 0.4 mL. The needle was inserted as tangentially as possible
to the skin surface, a few millimeters under the skin, just enough to
produce a visible wheal in the skin. Care must be taken to avoid any
skin contamination that could be confused with lymph node uptake.
The injection site was covered with a sticking plaster to prevent
leakage of tracer through the punctured skin.
Imaging Acquisition. After the radiotracer injection, an imme-
diate dynamic study (1 frame/30 s for 10 min; matrix size, 128 ·
128) was acquired using a single-head digital g-camera (E-Cam;
Siemens Healthcare). Several 5-min early static images (matrix
size, 256 · 256) were obtained after this dynamic study. Another
set of static images (delayed) was obtained 2 h later. Body con-
touring was achieved by placing a flat methacrylate source filled
with 37 MBq of 99mTc-pertechnetate behind the patient. The lo-
cation of SLNs was defined after obtaining all acquisition views to
ensure accurate marking of the site of SLNs on the overlying skin.
This sequential acquisition is helpful to clarify the criteria for SLN
identification on preoperative images.
The major criteria for identifying lymph nodes as SLNs are the
visualization of lymphatic ducts, the time of appearance, the lymph
node basin, and the intensity of lymph node uptake. The lymph node
with direct lymphatic connection to the injection site was labeled the
SLN, as were other nodes of delayed appearance in different
lymphatic basins not previously seen. Second-echelon nodes receive
drainage from an SLN, and these nodes were often visualized on
lymphoscintigraphy (mainly on delayed images) but were not
evaluated in the present study.
SLN biopsy was indicated when an ultrasound study without
suspicion of node involvement was obtained in these cases; the
second lymphoscintigraphic procedure was done in the same way
as the first, by a different member of the team. Special care was
taken with the site of injection (reviewing the previous photo-
graphs). Lymphoscintigraphy was obtained with the same protocol
as described for the first study. Both sets of images were evaluated
by 2 investigators with experience in this field for similarity of the
following parameters: lymphatic flow pattern, draining lymph
node basin, and location and number of SLNs. After the second
study, the patients underwent surgery, where the SLNs were detected
with the help of the handheld g-probe and subsequently harvested
for delayed histologic study.
The dissected tissue with the SLN was placed in 4% formalin
solution. No frozen sections were obtained. The SLN was separated
from surrounding adipose tissue, bisected, sliced, and embedded.
Subsequent serial sections were made. Conventional staining with
hematoxylin–eosin and immune histologic staining with S100 and
human melanoma black–45 were performed.
Data Analysis and Statistics
Results were expressed as mean and SD, and percentages or as
otherwise specified. The k-coefficient and the corresponding 95%
confidence interval were used to assess agreement between the 2
drainage patterns. The Lin concordance coefficient and the corre-
sponding 95% confidence interval were also used to evaluate con-
cordance between the number of lymph nodes in each procedure.
k- and Lin coefficients above 0.80 indicate excellent agreement,
between 0.61–0.80 substantial agreement, between 0.41–0.60 mod-
erate agreement, between 0.21–0.40 fair agreement, and lower than
0.20 poor agreement. Categoric data were compared using the Fisher
exact test. The analysis was performed using SAS software, version
9.1.3 (SAS Institute Inc.), and the level of significance was estab-
lished at 0.05 (2-sided).
RESULTS
In 3 of 71 patients, the ultrasound findings after the first
lymphoscintigraphy study were suggestive of lymph node
involvement, and subsequent fine-needle aspiration cytology
showed metastases in all 3 cases (2 in the inguinal zone and the
other in the axillary area). Thus, the second lymphoscintigraphy
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study for SLN biopsy was not performed on these patients
and only 68 patients were included in the study. Tables 1
and 2 show the principal characteristics of the primary
tumor and lymphatic drainage. Five different nuclear medi-
cine physicians with different levels of skill in this technique
were involved in the injection procedure and lymphoscinti-
graphic studies.
An excisional biopsy was previously performed on 63 of
these 68 patients, and the remaining 5 had a shave biopsy
with the primary melanoma left in place. The mean time
that elapsed from the biopsy procedure until the first
lymphoscintigraphy study was 17 d (range, 13–28 d). The time
between the first and second lymphoscintigraphy studies aver-
aged 19 d (range, 7–30 d). Thus, the time between the biopsy
and SLN procedure averaged 32 d (range, 23–45 d). All 68
patients showed lymphatic drainage from the injection site in
both studies, and at least 1 SLN was identified in all cases. In
19 patients (28%), the first lymphoscintigraphy study visual-
ized drainage to more than 1 lymphatic basin. Two of these 19
patients had the primary tumor in the upper extremities, and 1
patient had the melanoma in a lower limb. Most patients in this
subgroup (16/19, or 84%) presented with primary melanoma
on the trunk (n 5 9) or on the head and neck region (n 5 7).
When the primary tumor was on the trunk, head, or neck,
drainage to multiple lymphatic basins was significantly more
prevalent than when the primary tumor was on the limbs (P5
0.0021, Fisher exact test). This significance was nearly the
same in the second lymphoscintigraphic study (n 5 18
patients, with a similar distribution of primary locations; P 5
0.0028, Fisher exact test). Lymphatic drainage paths were iden-
tical for both studies in 65 of 68 patients (96%; k-coefficient,
0.98, with 95% confidence interval ranging from 0.91 to 1).
This similarity was found in the number of visualized SLNs
(171 in the first study and 173 in the second [Lin concordance
coefficient, 0.95, with 95% confidence interval ranging from
0.92 to 0.97]) and in the location of the different SLNs (SLNs
from lesions on the upper limbs were identically localized in
the axilla or epicondylar area in both studies; this situation was
the same for inguinal or popliteal SLNs from lower-limb mel-
anomas).
In 3 patients (4% of the total study population),
substantial differences were observed between the first
lymphatic mapping and the second. In these patients, the
melanoma was on the trunk (2 patients) or on the head and
neck (1 patient). An example of this different drainage pattern
is shown in Figures 1 and 2.
Eighty percent of patients showed from 1 to 3 SLNs in
both lymphoscintigraphy studies. When the primary tumor
was on the trunk or the head and neck, more SLNs were
depicted (#8). The number of SLNs visualized per patient
in the first and the second lymphoscintigraphy studies was
nearly identical (mean 6 SD, 2.51 6 1.29 and 2.54 6 1.35,
respectively. Some examples are depicted in Figures 3 and
4. In 5 patients (7%), in-transit SLNs were visualized in
both lymphoscintigraphy studies, with no difference be-
tween the two.
During surgery, a total of 177 SLNs (mean 6 SD, 2.6 6
1.44) were harvested (range, 1–9). This figure implies good
agreement with both sets of lymphatic mapping (Lin con-
cordance coefficient, 0.78 for the first study and 0.82 for the
second study). The case of 9 excised SLNs was in a patient
who had a primary melanoma on the scalp with bilateral
drainage to the cervical area and occipital region.
The pathologic study showed micrometastases (.0.2–2
mm) in 3 patients and macrometastases (.2 mm) in 6 patients.
These figures resulted in 9 of 68 patients (13%) having SLN
involvement.
DISCUSSION
Sappey’s work on lymphatic drainage of skin was ac-
cepted as correct by the medical community for over 100
y. In the 1970s, new information became available based on
lymphoscintigraphic studies of melanoma patients. Those
studies showed that lymphatic drainage was unpredictable,
especially in the trunk and in the head and neck areas.
Some authors even showed that following Sappey’s guide-
lines would predict drainage to the wrong lymph node field
in 30% of patients (10). So, lymphoscintigraphy now plays
an important role in defining the pattern of potential meta-
static spread through the lymphatic system from the pri-
mary lesion site and the regional nodal basins at risk (1,6).
The SLN has been shown to be predictive of nodal
involvement, and its pathologic status is a key prognostic
factor in patients with primary melanoma. Meticulously
performed lymphoscintigraphy is essential for reliable
SLN biopsy and serves several purposes: to point out the
TABLE 1
Topographic Distribution of Primary Lesions and Staging Characteristics of Study Cohort
Primary site Lower extremities Upper extremities Head/neck Trunk
No. of patients 23 9 12 24
Mean Breslow thickness (mm) 2.2 1.5 2.2 1.7
TNM pathologic stage IA (n 5 2) IA (n 5 2) IB (n 5 5) IA (n 5 4)
IB (n 5 8) IB (n 5 3) IIA (n 5 3) IB (n 5 11)
IIA (n 5 4) IIA (n 5 2) IIB (n 5 3) IIA (n 5 5)
IIB (n 5 6) IIB (n 5 1) IIIC (n 5 1) IIB (n 5 1)
IIIA (n 5 2) IIIB (n 5 1) IIIA (n 5 1)
IIIB (n 5 1) IIIB (n 5 2)
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draining lymph node field at risk for metastatic disease, to
indicate the number of SLNs, to help distinguish first-tier
nodes from secondary nodes, to detect SLNs in unpredict-
able locations, and to mark the location of the sentinel node
on the skin. SLN biopsy identifies node-negative patients,
for whom further treatment may not be indicated, thus
reducing the number of unnecessary lymphadenectomies
and avoiding complications such as lymphedema, delayed
wound healing, infection, and pain (9,11). Furthermore, SLN
biopsy can identify those clinically node-negative patients
who actually have occult nodal metastases.
By combining preoperative lymphoscintigraphy with
intraoperative detection assisted by a handheld g-probe
and blue dye, one can detect the SLN in nearly all patients.
With an interobserver agreement of more than 98%, cuta-
neous lymphoscintigraphy is particularly useful for lym-
phatic mapping of sites such as the head, neck, and trunk,
in which lymphatic flow to more than a single adjacent
predictable nodal group may vary from 40% to 75% (12).
At these sites, lymphoscintigraphy extends the predicted
area of ambiguous lymphatic drainage from primary axial
melanomas to 11 cm on either side of the midline or above
and below Sappey’s line (the gently curved line drawn on
the skin between a point 2 cm above the umbilicus and the
level of the second lumbar vertebra on the back) instead of
the usual limit of 2.5 cm from these lines when anatomic
guidelines are followed (13). This ability to reliably iden-
tify drainage routes enables lymphoscintigraphy to predict
more than 98% of the basins that contain lymph node me-
tastases (14). In the present study, lymphatic drainage was
correctly identified in all patients in both lymphoscintigraphy
studies.
The assessment of reproducibility of cutaneous lympho-
scintigraphy for SLN detection is of great importance. A
lack of reproducibility may increase false-negative rates and
the risk of melanoma recurrence. A few previous studies have
tackled this issue. Rettenbacher et al. (6) showed a reproduc-
ibility of 84% in their study group of 100 patients by injecting
TABLE 2
Lymphatic Drainage Distribution Depending on Localization of Primary Lesion of Cutaneous Melanoma
Localization of primary lesion Inguinal drainage Axillary drainage Cervical drainage Other drainage
Upper extremities U (n 5 7) Elbow and arm (n 5 1)
B (n 5 1)
Lower extremities U (n 5 23)
Trunk U (n 5 1) U (n 5 12) U (n 5 2) Intercostal (n 5 1)
B (n 5 1) B (n 5 4) B (n 5 1) Scapular (n 5 1)
Internal mammary (n 5 1)
Head/neck U (n 5 2) Preauricular (n 5 5)
B (n 5 3) Supraclavicular (n 5 2)
U 5 unilateral; B 5 bilateral.
FIGURE 1. Discordance between first (A–
C) and second (D–F) lymphoscintigraphy
studies of 47-y-old man with melanoma on
upper back. First study showed SLNs in left
supraclavicular area and left axilla. Second
study, performed 4 wk later, showed similar
supraclavicular drainage but absence of
radiotracer uptake in axilla.
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the tracer in 2 different approaches. First, they injected the
tracer intracutaneously at a 2- to 5-mm distance from either
the melanoma or the biopsy scar. On another day, they re-
peated the investigation, injecting the radiotracer intracutane-
ously exactly 10 mm from the previous injection site. In 59 of
these patients, the primary tumor was on the trunk, head, or
neck. This percentage was similar to what we found in the
current study, in which primary melanoma was located on the
trunk or the head and neck in 36 (53%) of 68 patients. In
another study, Kapteijn et al. (8) identified the same lym-
phatic drainage in both lymphoscintigraphy studies in 22
(88%) of 25 patients. In 3 cases, differences were observed
between the 2 sets of images, with the location of the primary
melanoma being the head and neck in 2 patients and an upper
limb in the third. These 2 studies are different in their design,
and it seems that only 1 investigator was involved in the
lymphoscintigraphic procedure.
With these 2 studies in mind, the objective of the current
study was to test the reproducibility of lymphoscintigraphic
findings in 2 separate lymphatic mapping procedures in the
same patient, using a strict protocol performed by nuclear
medicine physicians with expertise in this particular field.
The radiopharmaceutical was administered to all patients
around the tumor site or biopsy scar in an identical manner
but by a different nuclear medicine physician each time.
Two to 4 injections were given, depending on the length and
location of the lesion. Intradermal injection left a small-
volume (60.5 mL) skin wheal, because a larger dose tends to
cause spread into deeper layers and thus to different lym-
phatic ducts (15). The volume was identical in the first and
second scans (although slight variations are inevitable). In our
study, 96% concordance was observed between 2 studies on
the same patient. In 3 of 68 patients (4%), the location of
SLNs and lymphatic drainage routes could not be reproduced
in the second study. Differences in drainage patterns were
seen in 2 trunk melanomas and 1 head and neck melanoma.
These locations are the most likely to show variability in
lymphatic drainage. However, none of these patients had me-
tastases in the SLNs, and so the discrepancies did not lead to
any upstaging or downstaging. This high grade of concor-
FIGURE 2. Discordance between first (A–
C) and second (D–F) lymphoscintigraphy
studies of 53-y-old woman with melanoma
on central frontoparietal area. First study
showed SLNs bilaterally in cervical area.
Second study, performed 2 wk later,
showed similar drainage in left cervical area
but absence of SLN uptake in right cervical
location. Delayed images were performed
(#4 h) with same results.
FIGURE 3. Concordance between first (A–
C) and second (D–F) lymphoscintigraphy
studies of 34-y-old woman with central mel-
anoma on head. Second study was per-
formed 3 wk after first study. Despite this
location, clear drainage is observed in right
cervical area only. Both studies show similar
lymphatic pathway and number of nodes,
with little difference in uptake.
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dance could be influenced by the exact placement of the
radiotracer injections at the same locations.
In-transit SLNs were observed in 5 patients (7% of the
group) and were exactly the same in both studies. The
primary tumors were on the upper limb, lower limb, and trunk
(3 cases). Thus, a strong point in favor of lymphoscintigraphy
is that occasionally aberrant drainage can be reliably identified
(16,17). On the other hand, a hot spot does not always repre-
sent a lymph node but can be caused by accidental spillage
from the injection site or a drop of radiotracer, as well as the
well-known occurrence of lymphatic lakes. Following the pro-
cedure meticulously during lymphoscintigraphy is mandatory
for best results (16,18,19).
The finding that lymphoscintigraphy is not always re-
producible may be explained by small differences in injection
technique or by a variation in tracer particle composition
(although we always use the same radiotracer). Also, patient-
related factors such as previous exertion, body hydration, and
variation in the hydrostatic pressure of blood may play a role.
Finally, the time interval after excision of the melanoma may
be important because granulation tissue is gradually replaced
by more dense and compact fibrous tissue in the process of
wound healing (5,13). Some patients had their first scinti-
graphic study a few weeks after the primary lesion had been
excised, and it is conceivable that such recent interventions
influence to some extent the lymphatic drainage of the area
concerned. In the 2 previously mentioned reproducibility stud-
ies, the time interval before reinjection varied from 2 d to 4
wk, and similar or different injection site–to–tumor distances
for both lymphoscintigraphy examinations were used.
Another important aspect of this study concerns the number
of SLNs visualized during both studies, as well as the number
of nodes surgically excised and their concordance. We found
excellent concordance between the 2 mapping studies (95%),
with similar numbers of visualized SLNs (171 vs. 173). A few
slight differences were observed; in the second study 3
patients had a lymph node that had been missed in the first
study, whereas 2 patients had a lymph node missed in their
second study. The mean number of SLNs was almost identical
in both studies (2.51 vs. 2.54). During surgery, 177 SLNs were
harvested. Although in most patients the site and number of
SLNs seen on lymphoscintigraphy studies did not vary
between the 2 studies, we found that some SLNs were brighter
or fainter on one study versus the other. Although more
lymphatic nodes were excised during surgery than were
visualized on lymphoscintigraphy, none of those extra
nodes was metastatic. This final result could be in accordance
with Rettenbacher et al., who found additional SLNs by
extending the injection distance to the scar, but none of the
extra visualized SLNs showed metastatic involvement. Thus,
widening the injection distance from the site of the primary
tumor may increase the ambiguous zone of drainage, cross
a lymphatic watershed, or visualize additional basins not
really related to drainage of the tumor site (6,20). The classic
protocol for radiotracer injection is robust enough to avoid
variabilities, as can be confirmed from our own results. Ap-
plication of the injection far (1 cm) from the scar would be
recommended only in patients with scar hypertrophy or in-
flammation after excisional biopsy or in patients with no
visualization after standard injection technique. On the other
hand, the intraoperative use of both blue dye (or fluorescent
tracers) and a g-probe is of crucial importance to compensate
for the limitations of lymphoscintigraphy (21).
Finally, in our program a nuclear medicine physician in
training performs more than 50 lymphoscintigraphic procedures
per year for SLN biopsy in melanoma patients. The results of
this study demonstrate that a well-trained learning curve in this
procedure offers suitable reproducibility in such a technique.
CONCLUSION
A strict and meticulous procedure during injection and
imaging acquisition offers excellent reproducibility in lym-
phatic mapping even when performed by different teams.
However, the classic protocol of radiotracer injection is
FIGURE 4. Concordance between first (A–D) and second (E–H)
lymphoscintigraphy studies of 39-y-old woman with melanoma on
dorsum of right hand. Second study was performed 3 wk after first
study. Even with this unusual drainage to arm, reproducibility was
achieved in both lymphatic pathways (in-transit nodes and axillary
nodes).
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reproducible and reliable enough to guarantee SLN identifi-
cation, although a slight variation in isolated cases (especially
when primary lesions are located on the trunk or on the head
and neck regions) is inevitable.
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